Loading stock data…
HRMY
$30.18-0.81 (-2.61%)
Market ClosedLast close May 11
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harmony Biosciences Holdings, Inc. in the Healthcare sector is trading at $30.18. The stock is currently 26% below its 52-week high of $40.87, remaining 8.1% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why HRMY maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.18
Potential Upside
87.2%
Whystock Fair Value$56.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$44.27+46.7%
Range$28.00 – $85.00
Fundamentals
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.86B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.84
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.79%
Volume
Today's trading volume
750,272
Recent News
Earnings Miss: Harmony Biosciences Holdings, Inc. Missed EPS By 21% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ), which a week ago released...
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
Harmony Biosciences Holdings (HRMY) Valuation After Q1 2026 Earnings Miss And Profitability Concerns
Harmony Biosciences Holdings (HRMY) just posted Q1 2026 earnings that fell short of analyst expectations, with net income and earnings per share lower than a year ago. This pressured the stock despite reaffirmed full year guidance. See our latest analysis for Harmony Biosciences Holdings. At a share price of $31.42, Harmony Biosciences has a 30 day share price return of 13.76%, while the year to date share price return of 15.94% and 1 year total shareholder return of 7.83% suggest momentum...
Is Harmony Biosciences Holdings, Inc. (HRMY) One of The Best Small Cap Value Stocks to Buy?
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best small-cap value stocks to buy. On April 24, H.C. Wainwright reiterated a Buy rating on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) and a $55 price target. The bullish stance is in response to positive discussions with the company’s senior management, including President and CEO Jeff Dayno, […]
Should Harmony Biosciences’ Softer Q1 2026 Earnings and Upbeat Forecasts Require Action From HRMY Investors?
Harmony Biosciences Holdings, Inc. has released its Q1 2026 results, reporting net income of US$32.49 million versus US$45.56 million a year earlier, with diluted earnings per share from continuing operations easing to US$0.55 from US$0.78. Despite this year-over-year earnings decline, analyst expectations for Harmony’s future earnings strength and earnings-per-share growth remain constructive, underlining a contrast between near-term results and forward-looking sentiment. Now we’ll examine...